WORLD CONGRESS ON GASTROINTESTINAL CANCER

2023 World Congress on Gastrointestinal Cancer

 

28 June-1 July Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  1-O NALIRIFOX versus nab-paclitaxel gemcitabine in treatment-naive patients with mPDAC: additional results from the phase 3 NAPOLI 3 trial Emma Page Received Received
  1-SO A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma NAIMAH BOLAJI Received Received
  1-P Gastric cancer: Artificial intelligence, complex system analysis and simulation for best management Oleg Kshivets Received Received
  2-PD Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies IRBLleida IRBLleida Received Received
  2-SO Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with idh1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial Steve Waye Received Received
  3-SO Clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer: preliminary results from the multicenter B-REAL study Monica Niger Received Received
  4-PD Deep learning of pancreatic cancer histopathology images predicts recurrence after surgery Avelyn Wong Received Received
  4-SO Impact of molecular profiling on survival in patients with advanced biliary tract cancers Leony Antoun Received Received
  5-SO Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study Rebecca Oakes Received Received
  5-PD MONEO: Phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC) Maria Alsina Received Received
  5-P A Soluble resistance related calcium binding protein (Sorcin) up-regulates in the multi-drug resistant advanced gastric cancer patients Sushmita Ghosh Received Received
  7-PD Osemitamab plus capecitabine and oxaliplatin (CAPOX) as the first line treatment of advanced G/GEJ cancer-updated efficacy data per claudin 18.2 expression level from study TranStar102/TST001-1002-cohort C Sue Chen Received Received
  7-P Change in CA 19-9 after 8 weeks of first-line chemotherapy as a predictor of overall survival in patients with metastatic pancreatic ductal adenocarcinoma Jarrod Smith Received Received
  8-PD HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2 advanced stomach Cancer-Correlation of the antibody responses and clinical outcome Joshua Tobias Received Received
  9-PD Anti-HER2 therapy following ctDNA-identified ERBB2 amplification for patients with advanced gastric cancer: exploration of real-world outcomes and resistance mechanisms Sakti Chakrabarti Received Received
  9-O Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial Steve Waye Received Received
  10-SO Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification Rebecca Oakes Received Received
  11-SO Bemarituzumab for the Treatment of Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer: Final Analysis of a Randomized Phase 2 Trial (FIGHT) Utkarsha Singh Received Received
  12-PD Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort Marjolein Lansbergen Received Received
  13-SO Outcomes and a prognostic classifier in 130 patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade Giovanni Randon Received Received
  13-P Management of Metastatic Colorectal Cancer in Patients &8805;70 Years - A Single Center Experience Florian Huemer Received Received
  14-SO Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age =65 years subgroup Megan Fox Received Received
  15-PD Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments Mara Persano Received Received
  16-P Associations among patient-physician sex concordance, treatment practices, and survival outcomes in a population-based colon cancer cohort Philip Ding Received Received
  17-P Impacts of patient-reported non-hormonal symptoms on outcomes of patients with neuroendocrine neoplasms (NENs) Michael Sawyer Received Received
  17-PD Multicentric prospective study assessing clinical benefit of targeted treatment for patients with biliary tract cancers Monica NIger Received Received
  19-PD Finnish population-based metastatic colorectal cancer data collection study - comparison with the prospective RAXO study Pia Osterlund Received Received
  20-P Pseudoglandular pattern in hepatocellular neoplasms and its diagnostic value with cytokeratin immunostain Lee-Ching Zhu Received Received
  21-P GastroPanel: A blood test to triage dyspeptic patients with atrophic gastritis at risk of developing gastric adenocarcinoma Cinzia Papadia Received Received
  21-PD Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in metastatic colorectal cancer (mCRC) patients Martina Carullo Received Received
  22-PD RAS-mutations in population-based and real-life metastatic colorectal cancer cohorts Emerik Osterlund Received Received
  22-P Frequency of dihydropyrimidine dehydrogenase (DPD) deficiency detection and adverse events in patients receiving fluoropyrimidine-based therapy in a pancreatic and biliary tract cancer cohort Eve Wilson Received Received
  22-SO Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study Federica Marmorino Received Received
  23-P Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP Follow-up Study Hiroki Sameshima Received Received
  23-SO The influence of the microbiome on the tumour-immune microenvironment in colorectal cancer Rachel Purcell Received Received
  25-PD Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colo-rectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study Martin Köhler Received Received
  26-PD Efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal versus gastric cancers: a large, multicenter, cohort study Giacomo Mazzoli Received Received
  27-SO Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO Veronica Conca Received Received
  27-PD The use of pre-operative systemic oxaliplatin or irinotecan doublet chemotherapy in colorectal cancer peritoneal metastases (CRPM): Results from a single UK peritoneal tumour centre Nadina Tinsley Received Received
  28-P Locally advanced gastric cancer under FLOT - Real-world data on efficacy of patients with dMMR Lisa Goncalves Received Received
  28-PD Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis ANDRE Thierry Received Received
  31-P A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors Maria Apostolopoulou Received Received
  32-SO Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT) Marco Germani Received Received
  33-P The role of preoperative immune-chemotherapy in locally advanced resectable gastric cancer with microsatellite instability Henian Sun Received Received
  35-P Zanzalintinib (XL092) in combination with atezolizumab for previously treated metastatic colorectal cancer Jennifer Humbert Received Received
  48-P Outcomes of early gall bladder cancer (GBCA): A retrospective analysis from a tertiary care centre in India Joydeep Ghosh Received Received
  49-P Stereotactic body radiotherapy (SBRT) for liver metastasis. Institutional experience Maria Vera Merino Received Received
  51-P Epigenome-wide DNA methylation profiling identifies the TNXB gene as a potential epigenetic candidate for colorectal cancer prevention Manuel Macias Gonzalez Received Received
  54-P Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC) Francesca Salani Received Received
  56-P Brightline-2: a Phase IIa/IIb, open-label trial of the MDM2p53 antagonist brigimadlin (BI 907828) in patientswith advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinomaor other ed solid tumours Teresa Macarulla Received Received
  57-P Atezolizumab in combination with bevacizumab in patients with unresectable HCC previously untreated with systemic therapy: Interim analysis results from phase IIIb Italian AMETHISTA trial Cinzia Astolfi Received Received
  58-P An ongoing open-label, phase 2 trial of RP2 or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma Leilany Lopez Received Received
  60-P Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: A single-arm phase II clinical trial Ting Liu Received Received
  63-P Real-world UK retrospective multi-centre review of the use of G-CSF in the prevention of chemotherapy-induced neutropenia in patients with CRC receiving trifluridine/tipiracil Laura bell Received Received
  67-P Immune cell and microbiome contributions to radiotherapy response in rectal cancer Rachel Purcell Received Received
  68-P Impact of specimens and fixation status on HER2 assessment in the treatment of advanced gastric cancer (HER_WEEKEND study) Michio Nakamura Received Received
  77-P Multisite intratumoral chemotherapy improves treatment outcome in a murine model with pancreatic ductal adenocarcinoma Ron Epelbaum Received Received
  80-P Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study Takeshi Yamada Received Received
  82-P Impact of COVID-19 pandemic on metastatic colorectal cancer outcomes Mirjana Pavlovic Mavic Received Received
  90-P Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment Guglielmo Vetere Received Received
  91-P Landscape of BRAF-V600E mutant colorectal cancer management in Latin America Juan Manuel OConnor Received Received
  93-P Safety and feasibility of irradiation and nivolumab in esophageal cancer a phase I/II study Geir Olav Hjortland Received Received
  95-P Long-term effectiveness results and prognostic predictors for overall survival from CIREL the real-world multi-centre, observational cohort on irinotecan-eluting transarterial chemoembolization in CRLM Bleranda Zeka Received Received
  96-P Circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer treated with multimodal treatment Lorenzo Gervaso Received Received
  99-P Tumor treating fields (TTFields) are effective for treatment of gastric cancer cells, boosting the activity of FOLFOX Sinead Stewart Received Received
  104-P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001) Huimin Wang Received Received
  105-P COLSTAR study: Safety data on the first cohort of patients from the safety lead-in part of the study Steve Waye Received Received
  108-P An interplay between immune cells and microbiota drives the spontaneous regression of colorectal polyps in familial adenomatous polyposis pig model Wei Liang Received Received
  110-P Epidemiological and clinicopathological features of early- (EOPC) and late-onset pancreatic cancer (LOPC) patients (pts): A mono-institutional retrospective analysis Maria Bensi Received Received
  112-P Assessing the accuracy of CT staging for tumor and nodal staging in colon cancer Jingjing Yu Received Received
  113-P Evidence for early detection of metastatic variants and tumour evolution in ctDNA of patients with oesophageal adenocarcinoma Mark Openshaw Received Received
  114-P The therapeutic potential of nuclear receptor RORy in hepatocellular carcinoma Sabrina Leo Received Received
  116-P Clinical utility of circulating tumor DNA (ctDNA) in patients with early/resected biliary tract cancer (BTC) James Yu Received Received
  117-P Feasibility of tumor-informed circulating tumor DNA in neoadjuvant rectal cancer Charuta Palsuledesai Received Received
  118-P Clinical significance of primary tumor sites and epithelial tumor markers in patients with unresectable/recurrent gastrointestinal neuroendocrine carcinoma treated with combined chemotherapy with irinotecan and cisplatin Koshiro Fukuda Received Received
  119-P HGCSG 1803: single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment Kentaro Sawada Received Received
  120-P Efficacy of systemic therapy for advanced hepatocellular carcinoma based on etiology: a systematic review and network meta-analysis Charlene Hoi Lam Wong Received Received
  123-P CD73high biliary tract cancer (BTC) is a molecularly defined subtype with distinct clinical implications Pietro Carotenuto Received Received
  126-P TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: substudies in gastric and colorectal cancer Sian Budgen Received Received
  131-P Evaluation of predictive factors of toxicity of chemotherapy with FOLFIRINOX in patients treated for pancreatic adenocarcinoma Roland Eid Received Received
  132-P Underrepresentation of racial and ethnic minorities in metastatic colorectal carcinoma clinical trials within the United States Tracey Pu Received Received
  135-P Detection of RAS gene mutations in patients with metastatic colorectal cancer during cetuximab-based first-line treatment and survival of the patients in relation to changes in RAS gene status Marian Stresko Received Received
  137-P Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations Kelly Corona Received Received
  139-P Total neoadjuvant therapy for locally advanced rectal cancer: a UK cohort Mayumi Forster Received Received
  142-P Completion of genetic testing and incidence of pathogenic germline mutation among patients with early-onset colorectal cancer, a single institution retrospective analysis Zhaohui Jin Received Received
  144-P Characterisation of gastric tumour microbiota using isolation culture methodology and a novel gastric tumour bioreactor system Mary Booth Received Received
  146-P Efficacy and safety of FLOT combined with apatinib and sintilimab as a neoadjuvant therapy regimen for locally advanced gastric or gastroesophageal junction adenocarcinoma: an open-lable, single-arm, phase II study Huinian Zhou Received Received
  153-P Focus on RAS codon 61 mutations in metastatic colorectal cancer (mCRC): a retrospective analysis Francesco Schietroma Received Received
  154-P Using the EVendo score to predict varices and varices needing treatment in hepatocellular carcinoma patients planned for atezolizumab-bevacizumab Ching Han Toh Received Received
  156-P Efficacy and safety of cadonilimab combined with FLOT regimen as a neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma: a prospective, multicenter, open-label, single-arm phase II study Bo Long Received Received
  158-P The algorithm of esophagectomy technique ion in surgical treatment of squamous cell carcinoma and adenocarcinoma of esophagus Nikolay Khandogin Received Received
  159-P Association of acrochordons and colorectal polyps: a pilot study to identify potential genetic or viral etiology Bogdan Gafton Received Received
  162-P Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): a retrospective exploratory study Jing Huang Received Received
  164-P Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POL?)-mutated solid tumours in the GARNET study Steve Orlando Received Received
  167-P Type 2 diabetes as a predictive and prognostic factor in advanced pancreatic cancer: preliminary results of the Italian, observational PANCAKE study Federico Nichetti Received Received
  172-P VOLTAGE cohort D: preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancer Yusuke Takahashi Received Received
  173-P Extended molecular profiling in patients with biliary tract cancers: impact of the brcaness phenotype in patients management Virginia Genovesi Received Received
  174-P Outcomes in local gastric cancer resected without neoadjuvant therapy: a descriptive study Elisabet Bujons Buscarons Received Received
  175-P Next-generation sequencing in colorectal cancer patients: characterization and prognostic implications Federico Longo Received Received
  177-P Italian real world artificial intelligence (AI) based analysis of EaRly-onset COLorEctal cancer: the ERCOLE study Maria Alessandra Calegari Received Received
  180-P Efficacy and safety of anti-PD1 agents in patients with advanced GI malignancies: real-world data Sofia Montenegro Luis Received Received
  181-P Adoption of neoadjuvant immunotherapy in patients with deficient mismatch repair localized colorectal cancer: a National Cancer Database analysis Sakti Chakrabarti Received Received
  182-P Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer Rafael Rafael Received Received
  183-P BRAF mutant metastatic colon cancer expect the unexpected: a single centre study Mona Hassan Received Received
  186-P Efficacy of the combined chemotherapy regimens in elderly patients with advanced pancreatic cancer Mariam Manukyan Received Received
  187-P Targeting glutamine metabolism and EGFR in RAS wildtype metastatic colorectal cancer Kristen Ciombor Received Received
  189-P Surrogate endpoints in advanced gastroesophageal cancer: a systematic review and meta-analysis of phase III clinical trials IRBLleida IRBLleida Received Received
  190-P NALIRIFOX (liposomal irinotecan 5&8209;fluorouracil/leucovorin oxaliplatin) versus FOLFOX (5&8209;fluorouracil/leucovorin oxaliplatin) as first-line treatment of metastatic pancreatic ductal adenocarcinoma: real-world comparative overall survival analysis Emma Page Received Received
  195-P Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: a multicenter retrospective real-world study Carlo Signorelli Received Received
  197-P Clinical outcomes in patients with krukenberg tumors from colorectal cancer Arsha Ostowari Received Received
  202-P Topical diclofenac in prevention of capecitabine associated HFS in patients with GI cancers: an exploratory subgroup analysis of the D-ToRCH study Akhil Santhosh Received Received
  205-P Streamlining the diagnostic pathway for Lynch Syndrome in colorectal cancer patients: a ten-year experience in a single Italian center Alberto Puccini Received Received
  207-P Analysis of chemotherapy-induced subtype shifts in patient-derived tumoroids and parallels to functional in-vitro chemosensitivity testing in pancreatic ductal adenocarcinoma Tabea Sturmheit Received Received
  210-P Efficacy and tolerability of cetuximab 750 mg/m2 every three weeks in metastatic colorectal cancer Mohamed Aseafan Received Received
  218-P Oligometastatic Pancreatic Cancer: A Systematic Review and Synthesis of Consensus Carl-Stephan Leonhardt Received Received
  219-P Non-operative management of localized mismatch repair deficient colon cancer: a real-world perspective Sakti Chakrabarti Received Received
  220-P S-1 plus oxaliplatin versus capecitabine plus oxaliplatin chemotherapy in the treatment of patients with metastatic colorectal cancer: a meta-analysis John Kelvin Lalusis Received Received
  221-P Prediction of colon cancer recurrence based on proteomic biomarkers Soledad Cameselle-Garcia Received Received
  231-P Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2) Benjamin Weinberg Received Received
  232-P The predictive factors for identifying gastric cancer in patients with gastric indefinite for neoplasia lesions Hye-Su You Received Received
  233-P Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: a single-center study, updated with new data Stefani Ioannou Received Received
  235-P Association of stage shift and prior gastroscopy in patients with gastric cancer Yi-Hsin Yang Received Received
  236-P Aflibercept-based and bevacizumab-based second line regimens in patients with RAS mutant metastatic colorectal cancer: propensity score weighted-analysis from a multicenter cohort Jessica Lucchetti Received Received
  240-P Frequency and management of trifluridine/tipiracil (FTD/TPI) bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practice Nieves Martínez Lago Received Received
  245-P Survival after minimally invasive vs open surgery for pancreatic adenocarcinoma Joris Jaekers Received Received
  249-P Aflibercept-based and bevacizumab-based second line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: propensity score weighted-analysis from a multicenter cohort Lorenzo Angotti Received Received
  251-P Prospective validation of the Asian Pacific Colorectal Screening (APCS) score to detect colorectal neoplasia among Mexican subjects undergoing screening colonoscopy Monica Meneses-Medina Received Received
  252-P Comparison of second-line treatment after GEM/nab-PTX therapy for metastatic pancreatic cancer Kotaro Takeshita Received Received
  253-P Single agent immunotherapy in advanced oesophago-gastric (OG) cancer: an option for frail patients Grisma Patel Received Received
  256-P Albumin-bilirubin (ALBI) grade at 6 weeks post-diagnosis is a better prognosticator than baseline ALBI in intrahepatic cholangiocarcinoma Chi Fung Wong Received Received
  263-P Epidemiology and characteristics of low or normal AFP vs high AFP in hepatocellular carcinoma- retrospective experience in a tertiary care institute ANAND PRAVEEN KUMAR A Received Received
  266-P Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI) Darren Cowzer Received Received
  267-P Spatially resolved detection of premalignant lesions and immune-infiltration in gastric endoscopic biopsies using multiplexed immunofluorescence and correlation with OLGA/OLGIM assessment Franz Villarroel-Espindola Received Received
  268-P Using 16S rRNA gene sequencing to investigate the composition of Fusobacterium-associated microbiota and its impact on outcome in rectal cancer Stefania Napoli Received Received
  272-P Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune check-point inhibitor (ICI) therapy James Harding Received Received
  273-P Genomic alterations associated with aggressive histology and decreased overall survival in neuroendocrine malignancies Nicole Farha Received Received
  275-P FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers Federico Nichetti Received Received
  276-P Robust and cost effective in-vivo CAM models for drug combination study in colorectal cancer during covid-19 pandemic razia aslam Received Received
  277-P Real-world efficacy, safety, and impact of the GIPI score of nivolumab in advanced esophageal squamous cell carcinoma (ESCC) refractory or intolerant to prior chemotherapy in European population: the EPIC trial Antía Cousillas Castiñeiras Received Received
  278-P Survival impact and predictive scores for thrombosis associated with pancreatic ductal adenocarcinoma (PDAC) Alejandra Romano Received Received
  281-P Safety analysis and preliminary clinical results of REPROGRAM-01 phase II study evaluating regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer Angélique Vienot Received Received
  282-P Atezolizumab and bevacizumab in the treatment of advanced hepatocellular carcinoma - a single-center experience Nika Librenjak Received Received
  284-P Stereotactic body radiotherapy (SBRT) for liver metastasis of colorectal and anal cancer patients: clinical outcomes of a single centre experience Berta Martin-Cullell Received Received
  285-P Basket trials in upper gastrointestinal and hepato-pancreatico-biliary cancers an emerging entity Prerana Huddar Received Received
  287-P Retrospective real-world data study using natural language processing to describe treatment sequence and clinicopathological patterns in patients with metastatic colorectal cancer in five Spanish institutions Elena Garcia Arcelay Received Received
  290-P Treatment sequences and locoregional therapies for patients with carcinoid and refractory carcinoid syndrome. A multicentric cohort analysis ANA ISABEL OVIEDO ALBOR Received Received
  291-P Missing colorectal liver metastases after neoadjuvant chemotherapy: can we improve the prognosis? Elena Fernandez de Sevilla Received Received
  294-P The outcome of patients with mismatch repair deficient esophagogastric cancer receiving immunotherapy: A systematic review Sakti Chakrabarti Received Received
  300-P Progression free survival in patients with metastatic colorectal cancer treated with maintenance therapy with bevacizumab adjusted by sideness in a third level hospital in Mexico City ABDEL KARIM DIP BORUNDA Received Received
  307-P Serial ctDNA monitoring during immunotherapy (IO) in patients (pts) with MSI-H/dMMR advanced colorectal cancer (CRC) Shoshana Mehler Received Received
  311-P Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population in United States Lekha Yadukumar Received Received
  313-P Impact of COVID-19 on national trends of hospitalization and outcomes in pancreatic cancer patients presenting with venous thromboembolism in the United States Lekha Yadukumar Received Received
  316-P A retrospective study of gemcitabine with nab-paclitaxel as third line retreatment in advanced pancreatic adenocarcinoma Tara McSweeney Received Received
  320-P Immune checkpoint inhibitors (ICIs) vs chemotherapy as 3rd line regimen in patients with advanced gastric or esophageal (G/E) adenocarcinoma: A comparative study Brooke Wietharn Received Received
  327-P Comparison of clinicopathological and molecular features of two rare entities: Appendiceal carcinoma and small bowel adenocarcinoma Kreina Sharela Vega-Cano Received Received
  330-P ERBB2 mutations in metastatic colorectal cancer: from clinicopathological features to potential treatment implications in a real-world cohort caterina vaghi Received Received
  332-P Characteristic and clinical outcome of localized gastric cancer; real-world data Amal AlJuhani Received Received
  333-P Retrospective analysis of second-line chemotherapy after Folfirinox failure in advanced pancreatic cancer Yana Chikhareva Received Received
  336-P Neoadjuvant chemotherapy of the mFOLFIRINOX in the treatment of resectable pancreatic cancer Dayana Kantieva Received Received
  337-P Associate factors for endoscopic submucosal disection and postoperative delayed hemorrhage of colorectal neoplasm. Yong Wook Jung Received Received
  338-P Second line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first line treatment with gemcitabine and nab-paclitaxel Tara McSweeney Received Received
  342-P Prospective, observational study evaluating the effectiveness and safety of aflibercept plus FOLFIRI in metastatic colorectal cancer (mCRC) according to Polish reimbursement criteria Ragini Khajuria Received Received
  349-P An evidence-based patient resource program to improve the everyday lives of patients with metastatic gastrointestinal cancer Alberto Sobrero Received Received
  360-P Efficacy of regorafenib according to extended RAS evaluation: a multicenter retrospective analysis Giovanni Trovato Received Received
  368-P Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: a multicenter retrospective analysis Giulia Caira Received Received
  374-P Total neoadjuvant treatment of rectal cancer by MRI-guided radiotherapy Sven Van Laere Received Received
  376-P CoVigi Phase IV multicentric trial evaluating Covid-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2 specific antibody and T-cell response focused on patients with gastrointestinal tumors Radka Obermannova Received Received
  378-P Single institute experience of peri-operative FLOT chemotherapy Vikram Bansal Received Received
  379-P ARID1A as a prognostic biomarker in gastroesophageal cancer: a genomic database analysis Annalisa Schirizzi Received Received
  380-P Real world survival outcome in gastric cancer in a resource limited setting - an Indian experience Ruhi Kumar Received Received
  381-P Management of EaRly-onset MetastatIc cOlorectal caNcEr (ERMIONE): a single institution analysis Giustina Valente Received Received
  386-P Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer Mounia Foucart Received Received
  397-P Progression-free survival with maintenance therapy with fluoropyrimidine in patients with advanced gastric and gastroesophageal junction cancer in a third level hospital in Mexico City Alberto Pimentel Received Received
  402-P Six-months CA19.9 velocity as a predictive factor for relapse-free survival after curative pancreasectomy in pancreatic cancer Silvia Cesario Received Received
  403-P Rectal cancer in young patients - single center experience Vanessa Patel Received Received
  408-P Costa Rica, an example of the Americas in the implementation of an innovative organized colorectal screening program during 2017 2022 Jeffrey Jacobo Received Received
  410-P Factors affecting progression free survival (PFS) for patients with metastatic colorectal cancer (mCRC) receiving regorafenib or for patients after re-challenge previously effective chemotherapy (CT) regimens in third or following lines Evgenia Kuzmina Received Received
  411-P Pancreatic cancer oral inverse agonist of RORgT receptor targets primary cancer cells and alters inflammatory mediators of the tumor microenvironment Lynne Kelley Received Received
  415-P The importance of RAS and BRAF in metastatic colorectal cancer - real world evidence from North-East Romania Vlad Afrasanie Received Received
  419-P Safety and effectiveness analysis of neoadjuvant chemoradiation plus consolidative chemotherapy with concurrent anti-pd-1 therapy in mid-low locally advanced rectal cancer Xinliang Liu Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
18:32
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

2023 World Congress on Gastrointestinal Cancer

 

28 June-1 July Barcelona
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 28/06/2023 TO 28/06/2024
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert